[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100289723":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":46,"responsibleParty":110,"collaborators":26,"id":113,"slug":26,"hasResults":114,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":114,"sex":120,"minAge":121,"maxAge":122,"enrollmentInfo":123,"targetDuration":26,"studyType":126,"phases":127,"briefSummary":130,"conditions":131,"keywords":137,"overallStatus":49,"whyStopped":26,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":155},{"fullName":5,"class":6},"Sir Mortimer B. Davis - Jewish General Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Chemoradiation + EBRT Boost","EXPERIMENTAL","standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5; Complete responders and Non-complete responders",[13,14],"Procedure: Complete responders and Non-complete responders","Radiation: Chemoradiation + EBRT Boost",{"label":16,"type":10,"description":17,"interventionNames":18},"Chemoradiation + HDRBT Boost","standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions; Complete responders and Non-complete responders",[13,19],"Radiation: Chemoradiation + HDRBT Boost",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Complete responders and Non-complete responders","Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.",[9,16],null,{"type":28,"name":9,"description":29,"armGroupLabels":30,"otherNames":26},"RADIATION","45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5",[9],{"type":28,"name":16,"description":32,"armGroupLabels":33,"otherNames":26},"45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions",[16],[35],{"name":36,"affiliation":37,"role":38},"Te Vuong, MD","Sir Mortimer Jewish General Hospital","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Susanne Knoepfel","CONTACT","5143408288","21285","sknoepfel@jgh.mcgill.ca",[47,68,88,98],{"facility":48,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"UT Southwestern Medical Center","RECRUITING","Dallas","Texas","75390","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-96.80667,32.78306,{"lat":59,"lon":58},[62,66],{"name":63,"role":42,"phone":64,"phoneExt":26,"email":65},"Cristian Gonzales","214-645-5360","Cristian.Gonzalez@UTSouthwestern.edu",{"name":67,"role":38,"phone":26,"phoneExt":26,"email":26},"Aurelie Garant, MD",{"facility":69,"status":49,"city":70,"state":71,"zip":72,"country":73,"countryCode":74,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Le Centre Hospitalier de l'Université de Montreal","Montreal","Quebec","H2X0A9","Canada","CA",{"type":56,"coordinates":76},[77,78],-73.58781,45.50884,{"lat":78,"lon":77},[81,86],{"name":82,"role":42,"phone":83,"phoneExt":84,"email":85},"Nassima Taleb","514-890-8000","10812","nassima.taleb.chum@ssss.gouv.qc.ca",{"name":87,"role":38,"phone":26,"phoneExt":26,"email":26},"Carole Richard, MD",{"facility":89,"status":49,"city":70,"state":71,"zip":90,"country":73,"countryCode":74,"cosmosGeoPoint":91,"geoPoint":93,"contacts":94},"Jewish General Hospital","H3T 1E2",{"type":56,"coordinates":92},[77,78],{"lat":78,"lon":77},[95,97],{"name":41,"role":42,"phone":96,"phoneExt":44,"email":45},"514-340-8222",{"name":36,"role":38,"phone":26,"phoneExt":26,"email":26},{"facility":99,"status":49,"city":100,"state":71,"zip":101,"country":73,"countryCode":74,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Centre hospitalier universitaire de Québec","Québec","G2L2Z3",{"type":56,"coordinates":103},[104,105],-71.21454,46.81228,{"lat":105,"lon":104},[108],{"name":109,"role":42,"phone":26,"phoneExt":26,"email":26},"André-Guy Martin, MD",{"type":38,"investigatorFullName":111,"investigatorTitle":112,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Dr. Te Vuong","Director, Radiation Oncology Department","100289723",false,"NCT03051464","Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery","A Phase III Study Testing Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in the Context of Organ Preservation for Patients With Rectal Cancer","MORPHEUS","Inclusion Criteria:\n\n* Rectal cancer patients, clinically staged as T2-T3a,b N0-1 by MRI or endoscopic\u002Ftrans-rectal ultrasound\n* Rectal cancer staged as N0-1 by MRI or EUS\u002FTRUS\n* No metastatic lesion\n* Rectal tumor occupying less than half of the circumference\n* Tumor less than 5 cm on its largest dimension\n* Tumor located at less than 10 cm from the anal verge\n* Tumor penetration less than 5 mm in the mesorectal fat\n* Tumor accessible for brachytherapy\n* Lumen accessible for colonoscopy\n* Patient should be a suitable candidate for brachytherapy and chemotherapy\n* Older than 18 years of age\n* Adequate birth control measures in women of childbearing potential\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients with previous pelvic radiation\n* Evidence of distant metastasis\n* Extension of malignant disease to the anal canal\n* Tumors staged as T4\n* Tumors larger than 5 cm in length","ALL","18 Years","80 Years",{"count":124,"type":125},131,"ESTIMATED","INTERVENTIONAL",[128,129],"PHASE2","PHASE3","A randomized study of 131 patients. Patients with a clinical T2-3 N0-1 rectal cancer will be randomized to two arms (arm A: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy compared to arm B: standard chemoradiation (45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions).",[132,133,134,135,136],"Stage II Rectal Cancer","Organ Preservation","Non-operative Treatment","Rectal Cancer (Stage III)","Rectal Cancer Patients",[138,139,140,141,142,143,144,145],"rectal cancer","non-operative management","rectal preservation","organ preservation","brachytherapy boost for rectal cancer","low rectal cancer curative treatment","mid rectal cancer curative treatment","rectal brachytherapy","2026-06-25",{"date":148,"type":149},"2026-06-30","ACTUAL",{"date":151,"type":149},"2017-04-25",{"date":153,"type":125},"2030-01",{"name":5,"class":6},4]